Synthetically Modified Viral Capsids as Versatile Carriers for Use in Antibody-Based Cell TargetingAdel M. ElSohly, Matthew B. Francis, Chawita Netirojjanakul et al.|Bioconjugate Chemistry|2015Cited by 39
IKAROS levels are associated with antigen escape in CD19- and CD22-targeted therapies for B-cell malignanciesPablo Domizi, Kara L. Davis, Maria Caterina Rotiroti et al.|Nature Communications|2025Cited by 18
IKAROS facilitates antigen escape in the face of CD19- and CD22-targeted therapies for B-cell acute lymphoblastic leukemiaPablo Domizi, Kara L. Davis, Jolanda Sarno et al.|bioRxiv (Cold Spring Harbor Laboratory)|2024Cited by 2